Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leniolisib in APDS
NCT02435173Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2015
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 3 trial of leniolisib in activated phosphoinositide 3-kinase delta syndrome (APDS), sponsored by Novartis. Started Aug 2015; status: completed.
02
Drugs
leniolisib
03
Conditions
activated phosphoinositide 3-kinase delta syndrome (APDS)
Beyond the preview
Go deeper on NCT02435173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02435173.